Fructose-1,6-biphosphate prevents excitotoxic neuronal cell death in the neonatal mouse brain.
The excitotoxic cascade may represent an important pathway leading to brain damage and cerebral palsy. Brain lesions induced in newborn mice by ibotenate (acting on N-methyl-D-aspartate receptors) and by S-bromowillardiine (acting on alpha-3-amino-hydroxy-5-methyl-4-isoxazole propionic acid and kainate receptors) mimic some aspects of white matter cysts and transcortical necrosis observed in human perinatal brain damage. Fructose 1,6-biphosphate (FBP) is a high-energy glycolytic pathway intermediate which, in therapeutic doses, is non-toxic and neuroprotective in hypoxic-ischemic models of brain injury. Mechanisms of action include modulation of intracellular calcium through phospholipase C (PLC) activation. The goal of this study was to determine the neuroprotective effects of FBP in a mouse model of neonatal excitotoxic brain injury. Mice that received intraperitoneal FBP had a significant reduction in size of ibotenate-induced (80% reduction) or S-bromowillardiine-induced (40% reduction) cortical plate lesions when compared with control animals. Studies of fragmented DNA and cleaved caspase 3 confirmed the survival promoting effects of FBP. FBP had no detectable effect on excitotoxic white matter lesions. The effects of FBP were antagonized by co-administration of PLC, protein kinase C or mitogen-associated protein kinase inhibitors but not by protein kinase A inhibitor. A moderate, transient cooling of pups immediately after the insult extended the therapeutic window for FBP, as FBP administered 24 h after ibotenate was still significantly neuroprotective in these pups. This data extends the neuroprotective profile of FBP in neonatal brain injury and identifies gray matter lesions involving N-methyl-D-aspartate receptors as a major target for this promising drug.
Rogido
Marta
M
Division of Neonatology, Emory University, Atlanta, GA, USA.
Husson
Isabelle
I
Bonnier
Christine
C
Lallemand
Marie Christine
MC
Mérienne
Claude
C
Gregory
George A
GA
Sola
Augusto
A
Gressens
Pierre
P
D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D001921:Brain / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005635:Fructosediphosphates / Q000494:pharmacology*; D006863:Hydrogen-Ion Concentration; D007051:Ibotenic Acid / Q000494:pharmacology*; D019344:Lactic Acid / Q000378:metabolism; D008297:Male; D051379:Mice; D009026:Mortality; D009474:Neurons / Q000187:drug effects* / Q000502:physiology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009498:Neurotoxins / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
D004791:Enzyme Inhibitors; D005635:Fructosediphosphates; D018696:Neuroprotective Agents; D009498:Neurotoxins; C068592:5-bromowillardiine; D007051:Ibotenic Acid; D019344:Lactic Acid; C029063:fructose-1,6-diphosphate; D000409:Alanine